trending Market Intelligence /marketintelligence/en/news-insights/trending/JzPnAiYrpHw2-MsbfkSKvA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer acquires global license of drug program from Theravance for $10M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Pfizer acquires global license of drug program from Theravance for $10M

Pfizer Inc. agreed to acquire a global license for Theravance Biopharma Inc.'s program of certain enzyme inhibitors to treat skin conditions for an upfront cash payment of $10 million.

Under the agreement, New York-based Pfizer will pay Theravance up to an additional $240 million in development and sales milestone payments as well as royalties on worldwide net sales of any products developed under the program.

The program focuses on the development of therapies that targets Janus kinase, or JAK, a family of enzymes in the body. Currently, JAK inhibitors are used for the treatment of inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, myelofibrosis and ulcerative colitis.

Theravance's JAK inhibitors program is in the preclinical stage that covers activities prior to the testing of potential therapies in human subjects.